BioNTech and DualityBio Report Clinically Meaningful Efficacy for Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer BioPharm International
The purpose of this meta-analysis was to systematically assess the efficacy of ultrasound-guided therapy of ovarian endometriosis cyst (OEC). Several databases were searched to gather published studies on the efficacy …
Endometriosis (EMS) is a common gynecological disease that seriously affects women's health and quality of life. However, the detailed dynamic cellular and molecular mechanisms underlying EMS pathogenesis remain largely unknown. …
Background/Objectives: The diagnosis of endometriosis (EM) remains challenging due to the lack of a perfect diagnostic standard and the poor concordance between clinical symptoms and lesion severity. Although laparoscopy is …
Adenomyosis is a prevalent disorder of the archimetra, historically conflated with endometriosis but possessing a unique pathobiological trajectory. This review synthesises current molecular evidence to propose a unified mechanistic framework …
BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial BioSpace
Mitochondrial dysfunction has been demonstrated with a role in pathologically driving various obstetric and gynecological (OB/GYN) diseases, but molecular mediators associating mitochondrial dysfunction with discrete pathologies have not been determined …
Background/Objective: RNA modifications, including N6-methyladenosine (m6A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), N1-methyladenosine (m1A), pseudouridine (Ψ), N4-acetylcytidine (ac4C), 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) and adenosine-to-inosine (A-to-I) editing, constitute a critical layer of post-transcriptional regulation that …
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers National Today